Nebenwirkungen · Invokana
Invokana 100 mg film-coated tablets Invokana 300 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 15–16
HOS-128175 · Präparat HOS-096517
15 per 100 patient-years). Serious and severe renal-related events were also lower in the canagliflozin group versus placebo. The incidence rates of renal-related events were lower with canagliflozin relative to placebo across all three eGFR strata; the highest incidence rate of renal-related events was seen in the eGFR 30 to <45 mL/min/1.73 m2 stratum (9.47 vs 12.80 events per 100 patient-years for canagliflozin versus placebo, respectively).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-18T14:12:00Z · SHA-256 7067553c5dc97aae664e9160409281edb3ba1df3f3d4e6376eabc1ce3744693b · Passage 8019f298da6502ea0a363eef2e3210dd6521d459d146805251fd62572737d2fc · Zeichen 22095–22543 im Abschnitt